Inclusion Criteria:

          1. The subject has a histologic or cytologic diagnosis of a variant histology renal cell
             carcinoma including papillary, chromophobe, Xp.11 translocation, undifferentiated, or
             unclassified which is treatment naïve or has previously been treated with one systemic
             treatment line not containing any vascular endothelial growth factor antibody or
             vascular endothelial growth factor receptor tyrosine kinase inhibitors. The patient
             may have received treatment with immune checkpoint therapy including nivolumab as a
             single agent or nivolumab plus ipilimumab in combination. Previous treatment with
             mammalian target of rapamycin agents such as temsirolimus or everolimus is acceptable.

          2. Measurable disease per RECIST v1.1 as determined by the investigator.

          3. The subject has had an assessment of all known disease sites eg, by computerized
             tomography (CT) scan, magnetic resonance imaging (MRI), bone scan as appropriate,
             within 28 days before the first dose of cabozantinib or sunitinib.

          4. The subject is >/=18 years old on the day of consent;

          5. The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of
             </=2.

          6. Recovery to baseline or </= Grade 1 CTCAE v.4.0 from toxicities related to any prior
             treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive
             therapy;

          7. The subject has organ and marrow function and laboratory values as follows within 4
             days before the first dose of cabozantinib or sunitinib: a.The ANC >/= 1500/mm^3
             without colony stimulating factor support; b.White blood cell count >/= 2500/mm^3 (>/=
             2.5 GI/L). c.Platelets >/=100,000/mm^3; d.Hemoglobin >/= 9 g/dL; e. Bilirubin </= 1.5
             x the ULN. For subjects with known Gilbert's disease, bilirubin </= 3.0 mg/dL; f.Serum
             albumin >/= 2.8 g/dl g.Serum creatinine </= 2.0 X ULN or calculated creatinine
             clearance >/= 30 mL/min (>/= 0.5 mL/sec) using the Cockcroft-Gault equation: Males:
             (140 - age) x weight (kg)/(serum creatinine [mg/dL] × 72) Females: [(140 - age) x
             weight (kg)/(serum creatinine [mg/dL] × 72)] × 0.85 h.Alanine aminotransferase (ALT),
             aspartate aminotransferase (AST), and alkaline phosphatase (ALP) </= 3 X upper limit
             of normal (ULN). ALP </= 5 X ULN with documented bone metastases. i.Urine
             protein/creatinine ratio (UPCR) </= 1 mg/mg (</= 113.2 mg/mmol);

          8. The subject is capable of understanding and complying with the protocol requirements
             and has signed the informed consent document;

          9. Sexually active subjects (men and women) must agree to use medically accepted barrier
             methods of contraception (eg, male or female condom) during the course of the study
             and for 4 months after the last dose of study drug(s), even if oral contraceptives are
             also used. All subjects of reproductive potential must agree to use both a barrier
             method and a second method of birth control during the course of the study and for 4
             months after the last dose of study drug(s);

         10. Female subjects of childbearing potential must not be pregnant at screening. Females
             of childbearing potential are defined as premenopausal females capable of becoming
             pregnant (ie, females who have had any evidence of menses in the past 12 months, with
             the exception of those who had prior hysterectomy). However, women who have been
             amenorrheic for 12 or more months are still considered to be of childbearing potential
             if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, low body
             weight, ovarian suppression or other reasons.

        Exclusion Criteria:

          1. The subject has a variant histology that includes renal medullary carcinoma or
             collecting duct renal cell carcinoma. Any clear cell component in the tumor will lead
             to exclusion.

          2. The subject has received any previous anti-angiogenic agent. Prior treatment with
             cabozantinib.

          3. Radiation therapy for bone metastasis within 2 weeks, any other external radiation
             therapy within 4 weeks before the first dose of study treatment. Systemic treatment
             with radionuclides within 6 weeks before the first dose of study treatment. Subjects
             with clinically relevant ongoing complications from prior radiation therapy are not
             eligible;

          4. The subject has received any other type of investigational agent within 28 days before
             the first dose of study treatment;

          5. Known brain metastases or cranial epidural disease unless adequately treated with
             radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks
             before the first dose of study treatment. Eligible subjects must be neurologically
             asymptomatic and without corticosteroid treatment at the time of the start of study
             treatment;

          6. Concomitant anticoagulation with oral anticoagulants (eg, warfarin, direct thrombin
             and Factor Xa inhibitors) or platelet inhibitors (eg, clopidogrel). Allowed
             anticoagulants are the following: o Low-dose aspirin for cardioprotection (per local
             applicable guidelines) is permitted. o Low-dose low molecular weight heparins (LMWH)
             are permitted. Anticoagulation with therapeutic doses of LMWH is allowed in subjects
             without known brain metastases who are on a stable dose of LMWH for at least 6 weeks
             before first dose of study treatment, and who have had no clinically significant
             hemorrhagic complications from the anticoagulation regimen or the tumor.

          7. The subject has prothrombin time (PT)/INR or partial thromboplastin time (PTT)
             tes>/=1.3 X the laboratory ULN within 7 days before the first dose of study treatment.

          8. The subject has uncontrolled, significant intercurrent or recent illness including,
             but not limited to, the following conditions: Cardiovascular disorders: a.Congestive
             heart failure New York Heart Association Class 3 or 4, unstable angina pectoris,
             serious cardiac arrhythmias. b.Uncontrolled hypertension defined as sustained blood
             pressure (BP) > 150 mm Hg systolic or > 100 mm Hg diastolic despite optimal
             antihypertensive treatment. c.Stroke (including transient ischemic attack [TIA]),
             myocardial infarction (MI), or other ischemic event, or thromboembolic event (eg, deep
             venous thrombosis, pulmonary embolism) within 6 months before first dose.

          9. Continuation of 8:Gastrointestinal (GI) disorders including those associated with a
             high risk of perforation or fistula formation: The subject has evidence of tumor
             invading the GI tract, active peptic ulcer disease, inflammatory bowel disease (eg,
             Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or
             appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common
             bile duct, or gastric outlet obstruction. Abdominal fistula, GI perforation, bowel
             obstruction, or intra-abdominal abscess within 6 months before first dose.

         10. Continuation of 8: Clinically significant hematuria, hematemesis, or hemoptysis of >
             0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (eg,
             pulmonary hemorrhage) within 12 weeks before first dose. Cavitating pulmonary
             lesion(s) or known endotracheal or endobronchial disease manifestation. Lesions
             invading or encasing any major blood vessels. Other clinically significant disorders
             that would preclude safe study participation. Serious non-healing wound/ulcer/bone
             fracture. Uncompensated/symptomatic hypothyroidism. Moderate to severe hepatic
             impairment (Child-Pugh B or C).

         11. Major surgery (eg, GI surgery, removal or biopsy of brain metastasis) within 8 weeks
             before first dose of study treatment. Complete wound healing from major surgery must
             have occurred 1 month before first dose and from minor surgery (eg, simple excision,
             tooth extraction) at least 10 days before first dose. Subjects with clinically
             relevant ongoing complications from prior surgery are not eligible.

         12. Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms per
             electrocardiogram (ECG) within 28 days before first dose of study treatment

         13. Pregnant or lactating females.

         14. Inability to swallow tablets

         15. Previously identified allergy or hypersensitivity to components of the study treatment
             formulations.

         16. Diagnosis of another malignancy within 2 years before first dose of study treatment,
             except for superficial skin cancers, or localized, low grade tumors deemed cured and
             not treated with systemic therapy. Patients with Gleason 6 (3+3) prostate cancer with
             previous treatment or on active surveillance may also be allowed on protocol.

         17. The subject requires chronic concomitant treatment with strong CYP3A4 inducers (eg,
             dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine,
             phenobarbital, and St. John's Wort).